<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164980</url>
  </required_header>
  <id_info>
    <org_study_id>NOGGO S16/COMPASS</org_study_id>
    <nct_id>NCT03164980</nct_id>
  </id_info>
  <brief_title>Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer</brief_title>
  <acronym>COMPASS</acronym>
  <official_title>Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Eastern German Society of Gynaecological Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Clinical Cancer Research (IKF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>North Eastern German Society of Gynaecological Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, controlled, open-label study including patients with&#xD;
      recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer.&#xD;
&#xD;
      The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD&#xD;
      with other standard platinum-based chemotherapy in platinum-sensitive disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, controlled, open-label study including patients with&#xD;
      recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer.&#xD;
&#xD;
      The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD&#xD;
      with other standard platinum-based chemotherapy in platinum-sensitive disease.&#xD;
&#xD;
      Patients with recurrent, platinum-sensitive, ovarian, fallopian tube and peritoneal cancer&#xD;
      will be stratified according to surgery for relapse (R0 vs. R1/2 resection) vs. no surgery in&#xD;
      the same setting and age (&lt; 75 years vs. ≥ 75 years), and randomized 1:1 to receive either&#xD;
      trabectedin/PLD (Arm A) or one of 3 platinum-based standard therapies without bevacizumab&#xD;
      (Arm B, &quot;other standard therapy&quot;). In case of randomization to &quot;other standard therapy&quot;, the&#xD;
      investigator has the choice between carboplatin/PLD, carboplatin/gemcitabine and&#xD;
      carboplatin/paclitaxel. Patients in both treatment arms will receive chemotherapy up for 6&#xD;
      cycles or until disease progression (PD), unacceptable toxicities or patient's wish to stop&#xD;
      therapy, whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>observation of change in QoL</measure>
    <time_frame>3 month</time_frame>
    <description>QoL change from baseline (C1 D1) to after 3 months (± 2 week) or at progression, whichever occurs first. (EORTC QLQ-C30 in combination with EORTC QLQ-ov28)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in QoL</measure>
    <time_frame>12 month</time_frame>
    <description>measured at day one of every treatment cycle, at the end of the treatment and after 6 and 12 month (follow up) (EORTC QLQ-C30 in combination with EORTC QLQ-ov28).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Quality of Life</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin/PLD&#xD;
Carboplatin/Gemcitabine&#xD;
Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectidin (Yondelis)</intervention_name>
    <description>To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Women aged ≥ 18 years&#xD;
&#xD;
          2. Patients with histologically confirmed diagnosis of epithelial ovarian cancer, primary&#xD;
             peritoneal carcinoma or fallopian tube cancer who received ≥1 prior chemotherapy&#xD;
&#xD;
          3. Patients must be eligible for platin-containing therapy; Patient is defined as&#xD;
             platin-sensitive when considered for platin-containing therapy by the investigator.&#xD;
             The time frame from end of prior therapy until disease progression alone is not&#xD;
             pivotal for study participation. Patients without a platin-containing regimen in the&#xD;
             previous line who are also eligible for platin-containing regime are also appropriate&#xD;
             for participation&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2&#xD;
&#xD;
          5. Adequate baseline organ function as defined as&#xD;
&#xD;
               -  Leucocytes &gt; 3.0 x 109/l&#xD;
&#xD;
               -  Platelet count &gt; 100 x 109/l&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1500/mm3&#xD;
&#xD;
               -  Haemoglobin ≥ 9 g/dl&#xD;
&#xD;
               -  Alkaline Phosphatase (AP) ≤ 2.5 × ULN (consider hepatic isoenzymes 5 nucleotidase&#xD;
                  or gamma glutamyl transpeptidase (GGT), if the elevation could be osseous in&#xD;
                  origin)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN&#xD;
&#xD;
               -  Creatinine-Clearance ≥ 60 ml/min (MDRD formula or Cockroft &amp; Gault formula)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 mg/dl&#xD;
&#xD;
               -  Creatine phosphokinase (CPK) ≤ 2.5 × ULN&#xD;
&#xD;
               -  Total bilirubin &lt; ULN&#xD;
&#xD;
          6. Women of childbearing potential should use contraceptives or abstain from heterosexual&#xD;
             activity for the course of the study through 6 months after the last dose of study&#xD;
             medication or be surgically sterile.&#xD;
&#xD;
          7. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥ 50%&#xD;
             as determined by echocardiogram&#xD;
&#xD;
          8. Patients must provide written informed consent prior to performance of study specific&#xD;
             procedures or assessments, and must be willing to comply with treatment and follow up&#xD;
             assessments and procedures.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Only malignancies, which influence the prognosis&#xD;
&#xD;
          2. Any unstable or serious concurrent condition (e.g. active infection requiring systemic&#xD;
             therapy).&#xD;
&#xD;
          3. Chemotherapy or radiation therapy or tumor embolization within 2 weeks prior to the&#xD;
             first dose of study drug or planned during study participation.&#xD;
&#xD;
          4. Patients who have refractory disease. Refractory disease is defined if relapse occurs&#xD;
             &lt;4 months after beginning of platin-containing therapy.&#xD;
&#xD;
          5. Hypersensitivity to the active substance or to any of the excipients of study drug&#xD;
&#xD;
          6. Findings from ECG and/or assessment of LVEF which indicate an anthracycline-related&#xD;
             cardiotoxic process which contradicts administration of liposomal doxorubicin in&#xD;
             accordance with the requirements of the SmPC of PLD.&#xD;
&#xD;
          7. Biological therapy, immunotherapy, hormonal therapy or treatment with an&#xD;
             investigational agent within 14 days (for bevacizumab, 30 days) prior to the first&#xD;
             dose of study drug.&#xD;
&#xD;
          8. Any condition that is unstable or could jeopardize the safety of the patient and their&#xD;
             compliance in the study&#xD;
&#xD;
          9. Participation in another clinical study with experimental therapy within the 30 days&#xD;
             before start of and during treatment. Participation in a non-interventional study&#xD;
             should be discussed with sponsor and NC beforehand.&#xD;
&#xD;
         10. Patients in a closed institution according to an authority or court decision (AMG §&#xD;
             40, Abs. 1 No. 4)&#xD;
&#xD;
         11. Patients who are depending on the sponsor/CRO or investigational site as well as on&#xD;
             the investigator.&#xD;
&#xD;
         12. Pregnancy or lactation period, or planning to become pregnant within 7 months after&#xD;
             the end of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalid Sehouli, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annika Stürzebecher, Dr.</last_name>
    <phone>+49 30 403 68 65 41</phone>
    <email>annika.stuerzebecher@noggo.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maren Keller, Dr.</last_name>
    <phone>+49 30 403 68 65 32</phone>
    <email>maren.keller@noggo.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gertrud Strauch</last_name>
      <email>gstrauch@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Svetlana Tchaikovski, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elmar Stickeler, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyn-onkologische Schwerpunktpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>10317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sankt Gertrauden-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Platzer</last_name>
      <email>michaela.platzer@sankt-gertrauden.de</email>
    </contact>
    <investigator>
      <last_name>Jana Barinoff, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lidia Perlova-Griff, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isil Yalcinkaya</last_name>
      <phone>+(49)30450564404</phone>
      <email>isil.yalcin@charite.de</email>
    </contact>
    <investigator>
      <last_name>Jalid Sehouli, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Radoslav Chekerov, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena-Ioana Braicu, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Krebsheilkunde für Frauen</name>
      <address>
        <city>Berlin</city>
        <zip>13597</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amely Gärtner</last_name>
      <email>studien@medionko.de</email>
    </contact>
    <investigator>
      <last_name>Gülten Oskay-Özcelik, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steffen Gläser, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Bonn Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Herz</last_name>
      <email>s.herz@medizinisches-zentrum-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Christian Kurbacher, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jutta Kurbacher</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Studien GbR Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bibiana Kalensee</last_name>
      <email>kalensee@orenz-hecker-wesche.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Lorenz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janine Kreiss-Sender, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum Donauwörth</name>
      <address>
        <city>Donauwörth</city>
        <zip>86609</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Frauenklinik Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Griebsch</last_name>
      <phone>+(49)3514584202</phone>
      <email>Christine.griebsch@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Pauline Wimberger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theresa Link, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest gGmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Steinmetz</last_name>
      <email>steinmetz.kristina@khnw.de</email>
    </contact>
    <investigator>
      <last_name>Thorsten Götze, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timursah Habibzade</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Cieslik</last_name>
      <email>caroline.cieslik@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Maximilian Klar, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beate Rautenberg, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Fürth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Vincentius-Diakonissen-Kliniken g AG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>ZAGO am Helios Klinikum Krefeld</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Eberhardt</last_name>
      <email>iris.eberhardt@edizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Bahriye Aktas, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Najda Dornhöfer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik der Otto-von-Guericke-Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Seehase</last_name>
      <email>martina.seehase@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Marco Battista, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annette Hasenburg, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ruppiner Kliniken GmbH</name>
      <address>
        <city>Neuruppin</city>
        <zip>16816</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ina Lehmann</last_name>
      <email>I.Lehmann@ruppiner-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Bernd Christensen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cindy Kaesche</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sana Klinikum Offenbach</name>
      <address>
        <city>Offenbach</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Mantz</last_name>
      <email>beate.mantz@sana.de</email>
    </contact>
    <investigator>
      <last_name>Jens Kosse, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Khodaverdi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caritas Klinikum St. Theresia</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Schilling</last_name>
      <email>u.schilling@caritasklinikum.de</email>
    </contact>
    <investigator>
      <last_name>Mustafa Deryal, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mira Ebner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessika Strentzsch</last_name>
      <email>jessika.strentzsch@vinzenz.de</email>
    </contact>
    <investigator>
      <last_name>Manfred Hofmann, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Pentzlin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wilma Ehrle, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Dr. Horst Schmidt Kliniken Wiesbaden</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>amO Wolfsburg</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>platinum sensitive</keyword>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

